Table 1.

Number of strains initially screened for evidence of growth on 8 μg of fluconazole per mla

SerotypeMLEE genotypePrevalence (%)bTotal no. of strainsNo. of strains that did not growgNo. of strains that grewg
AET-16931427
ET-2101037
ET-35550
ET-44202
Unknown404
ADET-56c303
ET-6NAd101
ET-76c404
ET-216c505
DET-83e725
ET-93e312
ET-10NA101
ET-11NA110
ET-123e330
Unknown404
CET-13NA101
ET-16NA202
BET-14NA101
ET-15NA202
ET-17NA101
ET-181f202
ET-19NA110
Unknown514
UnclearUnknown202
Total1012180
  • a Data arranged by serotype and MLEE genotype as described previously (6-8).

  • b Prevalence of each ET (enzyme type) in four regions of the United States as determined by active surveillance (8).

  • c The prevalence of ET-5, ET-7, and ET-21 was determined as a group.

  • d NA, not available.

  • e The prevalence of ET-8, ET-9, and ET-12 was determined as a group.

  • f The prevalence of ET-18, ET-29, and ET-30 was determined as a group.

  • g Growth medium is YMA with 8 μg of fluconazole per ml.